Drug intelligence / Profile preview

tropenzilone

Development stage: Unknown
Modality: Small Molecules

Overview

Tropenzilone appears to be an older **synthetic anticholinergic antispasmodic** listed in the WHO ATC system, specifically under **A03DA01: tropenzilone and analgesics**, indicating use in combination products for painful gastrointestinal smooth-muscle spasm. Available modern source material is sparse, and I could not identify a well-documented contemporary monograph, manufacturer label, or development program that clearly defines its chemistry, formulation, or current regulatory status. Based on its ATC placement, it was used as a gastrointestinal antispasmodic and likely acted through **muscarinic cholinergic receptor antagonism** to reduce smooth-muscle contraction, but the exact receptor selectivity and product composition are not well characterized in the accessible sources.

Other names: tropenzilone

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on tropenzilone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tropenzilone.

Explore the full profile